← Leaderboards
Traci Lyons
University Of Colorado Denver
$4,705,520
Attributed
$5,446,818
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,446,818 · 5
By mechanism
R01$4,682,841 · 3
R41$392,695 · 1
R21$371,282 · 1
Top collaborators
- Virginia F. Borges2 shared
- Weston W Porter2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Heide L Ford$14,422,349
- Philip Reigan$2,271,458
- Alan Michael Elder$284,216
- John A Desisto$319,265
- Courtney Jo Fleenor$77,895
Others in their field
Top investigators on “Cessation Of Life”
- David R. Weir · University Of Michigan At Ann Arbor$345,522,974
- John M Lachin · George Washington University$134,302,892
- David M Nathan · Massachusetts Institute Of Technology$127,791,564
- Judith S Hochman · New York University School Of Medicine$112,898,313
- Jeffrey H Samet · Boston University Medical Campus$91,739,367
- Judith S. Currier · University Of California Los Angeles$85,330,415
Research focus
Cessation Of LifeSignal TransductionTumorMalignant Breast NeoplasmMediatingWomanYoung WomanNeoplastic CellTissuesMalignant NeoplasmsSemaphorinsBreast Cancer PatientClinically RelevantChildbirthMammary GlandBreast Cancer CellPostpartum PeriodNeoplasm MetastasisDiagnosisBreast Cancer DiagnosisClinical TrialsGene Expression ProfilingProtein ExpressionAffect
Grant awards (16)
A SIM2s/SEMA7A Switch Drives ER+ Breast Cancer Progression$545,485
R01 · FY2025 · CA · contact PI
SEMA7A in postpartum mammary gland development and cellular transformation$401,885
R01 · FY2025 · HD · contact PI
The development of humanized SEMA7A-antagonist mAbs for the therapeutic treatment of breast cancer$392,695
R41 · FY2025 · CA · contact PI
A SIM2s/SEMA7A Switch Drives ER+ Breast Cancer Progression$566,462
R01 · FY2024 · CA · contact PI
SEMA7A in postpartum mammary gland development and cellular transformation$397,867
R01 · FY2024 · HD · contact PI
SEMA7A in postpartum mammary gland development and cellular transformation$401,885
R01 · FY2023 · HD · contact PI
SEMA7A in postpartum mammary gland development and cellular transformation$406,185
R01 · FY2022 · HD · contact PI
Deciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.$355,706
R01 · FY2021 · CA · contact PI
Deciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.$421,578
R01 · FY2020 · CA · contact PI
Deciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.$345,034
R01 · FY2019 · CA · contact PI
Deciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.$63,896
R01 · FY2019 · CA · contact PI
Deciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.$355,706
R01 · FY2018 · CA · contact PI
AKT-mediated stabilization of SEMA7A as a driver of cell survival during mammary gland involution$65,446
R01 · FY2018 · CA · contact PI
Deciphering COX-2/SEMA7A dependent mechanisms of breast tumor progression.$355,706
R01 · FY2017 · CA · contact PI
(PQA1)Toward understanding mechanisms of COX-2 driven metastasis of breast cancer$169,061
R21 · FY2015 · CA · contact PI
(PQA1)Toward understanding mechanisms of COX-2 driven metastasis of breast cancer$202,221
R21 · FY2014 · CA · contact PI